Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers

NCT02777710 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer
Pancreatic Cancer
Metastatic Cancer
Advanced Cancer

Interventions

DRUG: Pexidartinib
DRUG: Durvalumab

Sponsor

Centre Leon Berard

Collaborators

[object Object]
[object Object]